CRL Charles River Laboratories International, Inc. Common Stock
$288,77
Cena · Sie 18, 2026
Dane fundamentalne na dzień Sie 5, 2026
Zakres 52 tyg.
$144–$289
100% of range
Ocena Analityków
BUY
22 analysts
Cena Docelowa
$281
P/E (TTM)
-99.2
ROE
-4.4%
Marża Zysku Netto
-3.6%
O Charles River Laboratories International, Inc. Common Stock Przegląd firmy z Wikipedii
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Czytaj więcej
Charles River Laboratories International, Inc. is an American pharmaceutical and biotechnology contract research organisation (CRO) headquartered in Wilmington, Massachusetts, United States. Founded in 1947, the company provides preclinical and clinical laboratory services for the development of new drugs, vaccines, and medical devices. Its operations span at least 20 countries, offering research models, safety assessment, and manufacturing support services to pharmaceutical, biotechnology, and government clients.
Charles River Laboratories is considered one of the largest CROs globally, known for its role in toxicology studies, animal research models, and microbial testing services used in regulatory submissions to health authorities such as the U.S. Food and Drug Administration (FDA). The company has also been the subject of public scrutiny and regulatory attention over its use of laboratory animals, including dogs, primates, and horseshoe crabs.
As of 2024, the company employs over 20,000 people worldwide and is publicly traded on the New York Stock Exchange under the ticker symbol CRL.
History
Charles River was founded in 1947 by Henry Foster, a young veterinarian who purchased one thousand rat cages from a Virginia farm and set up a one-person laboratory in Boston overlooking the Charles River. He supplied local researchers with laboratory animals.
In 1955, the company's headquarters were relocated to their current home in Wilmington, Massachusetts. The organization became an international entity in 1966 by opening a new animal production facility in France.
The first commercial, comprehensive genetic monitoring program was implemented by Charles River in 1981. Three years later, they were acquired by Bausch & Lomb. In 1988, the organization began creating transgenic mice and rats. In the 1990s, they began in vitro endotoxin testing. In the 1990s, Jim Foster bought Charles River back from Bausch & Lomb, and the company later went public on the New York Stock Exchange.
Charles River launched the Humane Care Imperative in 2002, designed to raise awareness and train employees on animal welfare's importance. The same year, they were named "Company of the Year" by The Boston Globe. The company introduced preconditioning services in 2005 to provide customers with study-ready animals.
In 2008, Charles River signed a ten-year contract to partner with the National Cancer Institute and opened a facility in Frederick, Maryland.
In April 2019, Charles River announced it would cease its San Diego operations, moving the breeding of rodents for testing compounds to Hollister, California.
In March 2023, the Born Free USA animal welfare organization protested against Charles River's plan to export 1,000 endangered juvenile long-tail macaques to Cambodia for testing.
Acquisitions
In 1988, Charles River purchased Specific Pathogen Antigen Free Avian Services (SPAFAS) and serologic diagnostic services Merck, Sharp, and Dohme.
Between 1996 and 2000, the company acquired Endosafe, Inc. and Sierra Biomedical.
In October 2003, Charles River Laboratories merged with Inveresk, a research company based in the United Kingdom. The company was known then as Charles River Laboratories. Inveresk specialised in clinical research and pre-clinical testing, and their main facilities are in Edinburgh, Scotland. In late 2009, Charles River sold its Clinical Services Division in Edinburgh to Quotient Bioresearch.
In 2010, Charles River Laboratories attempted to acquire WuXi PharmaTech, a China-based contract research organization, but the offer was withdrawn when the deal faced opposition from several large Charles River investors, including Relational Investors, JANA Partners, and Neuberger Berman. The proxy advisory firm RiskMetrics had also recommended that Charles River's shareholders vote against the proposed deal.
From 2008 to 2013, Charles River acquires several companies including NewLab Bioquality AG, MIR Preclinical Services, Piedmont Research Center, LLC, Cerebricon, Ltd., Accugenix, and Vital River, allowing the company to expand their research models and services portfolio to drug development and discovery markets in China.
The acquisitions of Argenta and BioFocus in 2014 allowed Charles River to establish itself as a full-service, early-stage contract research organization with integrated in vitro and in vivo capabilities from target discovery through pre-clinical development.
In July 2015, the company announced it would acquire Celsis International for $212 million.
In 2016, the company announced it was set to acquire WIL Research for approximately $585 million in cash and Blue Stream Laboratories.
In August 2017, the business announced it would acquire Brains On-Line.
In January 2018, the company announced it would acquire KWS BioTest for up to £18 million ($24.4 million). In February of the same year, Charles River announced it would acquire MPI Research for approximately $800 million in cash. The transaction was completed on April 3, 2018.
In February 2019, the company announced it would acquire Citoxlab for €448 million in cash (approximately $500 million), including the former acquisitions of the French company, AccelLAB, Atlanbio and Solvo Biotechnology. The transaction was completed on April 29. In December of the same year the business announced it would acquire HemaCare for approximately $380 million in cash.
In August 2020, the company announced it would acquire Cellero for $38 million in cash.
In January 2021, the company announced it would acquire Distributed Bio, Inc., an antibody discovery business.
In February 2021, Charles River announced it would acquire Cognate BioServices, Inc. for $875 million.
In March 2021, Charles River announced the acquisition of Retrogenix for $48 million.
In May 2021, Charles River announced the acquisition of Vigene Biosciences, a gene therapy contract development and manufacturing organization (CDMO), for $292.5 million.
In October 2021, a Japanese subsidiary of Charles River was acquired by Jackson Laboratory for $63M USD.
In April 2022, the company announced it would acquire Explora BioLabs.
In January 2023, the business announced it would acquire SAMDI Tech, Inc.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
CRL Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
Cena
$288.77
Kapitalizacja Rynkowa
$14.21B
P/E (TTM)
-99.2
EPS (TTM)
$-2.91
Przychody (TTM)
$4.02B
Stopa dywidendy
—
ROE
-4.4%
D/E Dług/Kapitał
0.0
Zakres 52 tyg.
$144 – $289
CRL Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Configure
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Przychody i Zysk Netto
$4.02B
2016-12-31
→
2025-12-27
EPS
$-2.91
2016-12-31
→
2025-12-27
Wolny przepływ pieniężny
$518M
2016-12-31
→
2025-12-27
Marże
-3.6%
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
Wskaźnik
Trend 5-letni
CRL
Mediana porównawcza
P/E (TTM)
-99.2
39.9
P/S (TTM)
3.5
5.6
P/B
4.5
4.1
EV / EBITDA
32.7
—
Price / FCF (Cena / FCF)
27.4
—
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
Wskaźnik
Trend 5-letni
CRL
Mediana porównawcza
Operating Margin (Marża Operacyjna)
0.63%
—
Net Profit Margin (Marża Zysku Netto)
-3.6%
11.7%
ROA
-2.0%
4.7%
ROE
-4.4%
8.5%
ROIC
1.1%
—
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
Wskaźnik
Trend 5-letni
CRL
Mediana porównawcza
Debt / Equity (Dług / Kapitał Własny)
0.0
15.3
Current Ratio (Wskaźnik bieżący)
1.3
1.7
Quick Ratio (Wskaźnik Szybkości)
0.8
—
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
Wskaźnik
Trend 5-letni
CRL
Mediana porównawcza
Revenue YoY (Przychody R/R)
-0.85%
—
Revenue CAGR 3Y (Przychody CAGR 3L)
0.33%
—
Revenue CAGR 5Y (Przychody CAGR 5L)
6.6%
—
EPS YoY
-97.8%
—
Net Income YoY (Zysk Netto R/R)
-95.3%
—
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
Wskaźnik
Trend 5-letni
CRL
Mediana porównawcza
CRL Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
KUP
22 analityków
- Mocne kupno 5 22,7%
- Kup 10 45,5%
- Trzymaj 7 31,8%
- Sprzedaj 0 0,0%
- Mocna sprzedaż 0 0,0%
12-miesięczny cel cenowy
14 analityków · 2026-08-14
Mediana
$300.00
Średnia
$281.00
Teraz
$288.77
Niski
$145.00
Wysoki
$318.00
Średni cel
$300.00
+3,9%
Średnia cel
$281.00
-2,7%
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
Średnie zaskoczenie
0.21%
| Okres | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|
| 30 czerwca 2026 | $3.02 | $2.76 | 0.26% |
| 31 marca 2026 | $2.06 | $1.96 | 0.10% |
| 31 grudnia 2025 | $2.39 | $2.37 | 0.02% |
| 30 września 2025 | $2.43 | $2.36 | 0.07% |
| 30 czerwca 2025 | $3.12 | $2.52 | 0.60% |
| 31 marca 2025 | $2.34 | $2.10 | 0.24% |
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | — |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | — |
| TECH | $7.97B | 111.8 | 5.2% | 6.0% | 3.7% | 64.8% |
| BIO | — | — | — | — | — | — |
| RGEN | $9.23B | 190.5 | 16.4% | 6.6% | 2.4% | — |
| TEM | — | -41.9 | 83.4% | -19.3% | -61.2% | — |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat 15
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Cost of Revenue | · | · | · | · | · | · | · | · | $290M | $277M | $264M | $266M | |
| SG&A Expense | $743M | $751M | $748M | $665M | $620M | $529M | $518M | $444M | $371M | $365M | $300M | $269M | |
| Operating Income | $25M | $227M | $617M | $651M | $590M | $433M | $351M | $331M | $288M | $238M | $206M | $178M | |
| Interest Expense | · | · | $137M | $59M | $74M | $86M | $61M | $64M | $30M | $28M | $15M | $12M | |
| Interest Income | $5M | $9M | $5M | $780.0K | $652.0K | $834.0K | $2M | $812.0K | $690.0K | $1M | $1M | $1M | |
| Other Non-op | $-23M | $-17M | $96M | $31M | $-36M | $100M | $12M | $13M | $38M | $12M | $3M | $11M | |
| Pretax Income | $-100M | $93M | $581M | $623M | $481M | $447M | $304M | $282M | $297M | $223M | $195M | $178M | |
| Income Tax | $43M | $68M | $101M | $130M | $82M | $82M | $50M | $54M | $171M | $67M | $43M | $48M | |
| Net Income | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 | $7.35 | $5.17 | $4.72 | $2.60 | $3.29 | $3.21 | $2.72 | |
| EPS (Diluted) | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 | $7.20 | $5.07 | $4.62 | $2.54 | $3.23 | $3.13 | $2.66 | |
| Shares (Basic) | 49,564,000 | 51,380,000 | 51,227,000 | 50,812,000 | 50,293,000 | 49,550,000 | 48,730,000 | 47,947,000 | 47,481,000 | 47,014,000 | 46,496,000 | 46,627,000 | |
| Shares (Diluted) | 49,564,000 | 51,628,000 | 51,451,000 | 51,301,000 | 51,425,000 | 50,611,000 | 49,693,000 | 49,018,000 | 48,564,000 | 47,958,000 | 47,634,000 | 47,558,000 | |
| EBITDA | $428M | $589M | $931M | $955M | $855M | $668M | $549M | $493M | $419M | $364M | $301M | $274M |
Bilans 30
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $214M | $195M | $277M | $234M | $241M | $228M | $238M | $195M | $164M | $118M | $118M | $160M | |
| Short-term Investments | · | · | · | · | $1M | $1M | $941.0K | $885.0K | $28M | $4M | $21M | · | |
| Receivables | $709M | $721M | $780M | $752M | $643M | $618M | $514M | $472M | $430M | $364M | $270M | $258M | |
| Inventory | $299M | $279M | $380M | $256M | $199M | $186M | $161M | $128M | $115M | $96M | $94M | $89M | |
| Prepaid Expense | $129M | $106M | $83M | $108M | $97M | $73M | $56M | $49M | $81M | $45M | $47M | $45M | |
| Other Current Assets | · | · | · | · | · | $0 | $300.0K | $300.0K | $0 | $45M | $47M | $73M | |
| Current Assets | $1.45B | $1.40B | $1.61B | $1.44B | $1.27B | $1.20B | $1.02B | $898M | $827M | $657M | $559M | $579M | |
| PP&E (Net) | $1.66B | $1.60B | $1.64B | $1.47B | $1.29B | $1.12B | $1.04B | $933M | $782M | $756M | $678M | $677M | |
| PP&E (Gross) | $3.19B | $3.06B | $2.98B | $2.63B | $2.39B | $2.21B | $2.02B | $1.81B | $1.58B | $1.46B | $1.32B | $1.33B | |
| Accum. Depreciation | $1.54B | $1.45B | $1.34B | $1.16B | $1.10B | $1.09B | $978M | $874M | $801M | $706M | $645M | $655M | |
| Goodwill | $2.76B | $2.85B | $3.10B | $2.85B | $2.71B | $1.81B | $1.54B | $1.25B | $805M | $788M | $439M | $321M | |
| Intangibles | $340M | $723M | $864M | $955M | $1.06B | $788M | $689M | $611M | $370M | $394M | $281M | $281M | |
| Other Non-current Assets | $293M | $278M | $309M | $148M | $152M | $353M | $213M | $144M | $124M | $88M | $72M | $73M | |
| Total Assets | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Accounts Payable | $149M | $140M | $169M | $206M | $198M | $122M | $111M | $66M | $78M | $68M | $37M | $34M | |
| Accrued Liabilities | $270M | $232M | $228M | $220M | $229M | $150M | $139M | $107M | $90M | $84M | $89M | $67M | |
| Current Liabilities | $1.12B | $994M | $1.06B | $1.09B | $1.03B | $840M | $710M | $558M | $464M | $430M | $312M | $295M | |
| Capital Leases | $434M | $484M | $419M | $390M | $253M | $156M | $116M | · | · | · | · | · | |
| Deferred Tax | $95M | $107M | $191M | $216M | $240M | $217M | $167M | $144M | $90M | $56M | $48M | $23M | |
| Other Non-current Liabilities | $138M | $195M | $223M | $175M | $243M | $205M | $183M | $179M | $195M | $159M | $89M | $100M | |
| Total Liabilities | $3.92B | $4.02B | $4.54B | $4.58B | $4.43B | $3.35B | $3.03B | $2.52B | $1.87B | $1.86B | $1.30B | $1.17B | |
| Long-term Debt | · | · | · | · | · | · | · | $1.61B | $1.09B | $1.18B | $814M | $717M | |
| Total Debt | $166.0K | $155.0K | $3M | $1M | $101.0K | $47M | $36M | $1.65B | $1.12B | $1.21B | $836M | $754M | |
| Common Stock | $492.0K | $511.0K | $513.0K | $509.0K | $505.0K | $498.0K | $489.0K | $482.0K | $875.0K | $863.0K | $855.0K | $845.0K | |
| Retained Earnings | $1.39B | $1.81B | $1.89B | $1.43B | $981M | $625M | $280M | $42M | $289M | $165M | $11M | $-139M | |
| Treasury Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $55.0K | $1.66B | $1.55B | $1.54B | $1.42B | |
| AOCI | $-172M | $-317M | $-196M | $-262M | $-165M | $-139M | $-178M | $-173M | $-145M | $-254M | $-136M | $-74M | |
| Stockholders' Equity | $3.16B | $3.46B | $3.60B | $2.98B | $2.53B | $2.11B | $1.63B | $1.32B | $1.05B | $837M | $733M | $672M | |
| Liabilities + Equity | $7.14B | $7.53B | $8.20B | $7.60B | $7.02B | $5.49B | $4.69B | $3.86B | $2.93B | $2.71B | $2.07B | $1.87B | |
| Shares Outstanding | 49,217,000 | 51,141,000 | 51,338,000 | 50,944,000 | 50,480,000 | 49,767,000 | 48,936,000 | 48,209,000 | 47,402,000 | 47,363,000 | 46,698,000 | 47,327,000 |
Przepływy pieniężne 18
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $403M | $362M | $314M | $304M | $266M | $235M | $198M | $162M | $131M | $127M | $95M | $96M | |
| Stock-based Comp | $71M | $70M | $72M | $74M | $71M | $56M | $57M | $47M | $44M | $44M | $40M | $31M | |
| Deferred Tax | $-75M | $-67M | $-51M | $-33M | $-20M | $2M | $-21M | $-10M | $28M | $3M | $4M | $9M | |
| Amort. of Intangibles | $179M | $138M | $137M | $147M | $125M | $112M | $90M | $65M | $41M | $42M | $24M | $26M | |
| Restructuring | $100M | $107M | $30M | $8M | $7M | $13M | $14M | $10M | $5M | $18M | $8M | $8M | |
| Other Non-cash | $483M | $348M | $-126M | $-211M | $53M | $-111M | $-5M | $16M | $-8M | $-28M | $-395.0K | · | |
| Operating Cash Flow | $738M | $735M | $684M | $620M | $761M | $547M | $481M | $441M | $318M | $317M | $307M | $252M | |
| CapEx | $219M | $233M | $319M | $325M | $229M | $167M | $141M | $140M | $82M | $55M | $63M | $57M | |
| Investing Cash Flow | $-209M | $-245M | $-563M | $-608M | $-1.44B | $-602M | $-682M | $-955M | $-73M | $-693M | · | · | |
| Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | $237M | $1.04B | · | · | |
| Net Debt Issued | $1.23B | $1.08B | $776M | $2.95B | $6.95B | $2.23B | $3.36B | $2.76B | · | · | · | · | |
| Stock Repurchased | $361M | $119M | $24M | $39M | $41M | $24M | $18M | $14M | $107M | $12M | $117M | $122M | |
| Net Stock Activity | $-361M | $-119M | $-24M | $-39M | $-41M | $-24M | $-18M | $-14M | $-107M | $-12M | $-117M | $-122M | |
| Financing Cash Flow | $-537M | $-551M | $-86M | $-42M | $673M | $47M | $232M | $558M | $-208M | $381M | · | · | |
| Net Change in Cash | $10M | $-79M | $43M | $-5M | $13M | $-7M | $43M | $31M | $46M | $-69.0K | $-43M | $4M | |
| Taxes Paid | $120M | $126M | $90M | $76M | $75M | $60M | $54M | $68M | · | · | · | · | |
| Free Cash Flow | $518M | $502M | $365M | $295M | $532M | $380M | $340M | $301M | $236M | $245M | $225M | $195M | |
| Levered FCF | · | · | $252M | $248M | $471M | $309M | $290M | $250M | $223M | $226M | $213M | $186M |
Rentowność 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% | 14.8% | 13.4% | 14.6% | 15.5% | 14.1% | 15.1% | 13.7% | |
| Net Margin | -3.6% | 0.55% | 11.5% | 12.2% | 11.0% | 12.5% | 9.6% | 10.0% | 6.6% | 9.2% | 10.9% | · | |
| Pretax Margin | -2.5% | 2.3% | 14.1% | 15.7% | 13.6% | 15.3% | 11.6% | 12.4% | 16.0% | 13.3% | 14.3% | 13.7% | |
| EBITDA Margin | 10.7% | 14.5% | 22.6% | 24.0% | 24.2% | 22.8% | 20.9% | 21.8% | 22.5% | 21.6% | 22.1% | 21.1% | |
| ROA | -2.0% | 0.28% | 6.0% | 6.7% | 6.2% | 7.1% | 5.9% | 6.7% | 4.4% | 6.5% | 7.6% | · | |
| ROE | -4.4% | 0.63% | 14.4% | 17.6% | 16.8% | 19.4% | 17.1% | 19.2% | 13.1% | 19.7% | 21.2% | · | |
| ROIC | 1.1% | 1.8% | 14.2% | 17.3% | 19.3% | 16.4% | 17.6% | 9.0% | 5.6% | 8.1% | 10.2% | 9.1% |
Płynność i wypłacalność 5
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 | 1.4 | 1.4 | 1.6 | 1.8 | 1.5 | 1.8 | 2.0 | |
| Quick Ratio | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 | 1.0 | 1.1 | 1.2 | 1.3 | 1.1 | 1.2 | 1.4 | |
| Debt / Equity | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.3 | 1.1 | 1.4 | 1.1 | 1.1 | |
| LT Debt / Equity | · | · | · | · | · | · | · | 1.2 | 1.0 | 1.4 | 1.1 | 1.1 | |
| Interest Coverage | · | · | 4.5 | 11.0 | 8.0 | 5.0 | 5.8 | 5.2 | 9.7 | 8.6 | 13.7 | 14.9 |
Efektywność 3
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.6 | 0.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | |
| Inventory Turnover | · | · | · | · | · | · | · | · | 2.7 | 2.9 | 2.9 | 3.0 | |
| Receivables Turnover | 5.6 | 5.4 | 5.4 | 5.7 | 5.6 | 5.2 | 5.3 | 5.0 | 4.7 | 5.3 | 5.2 | 5.4 |
Stopy Wzrostu 7
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | -0.85% | -1.9% | 3.9% | 12.3% | 21.1% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 0.33% | 4.6% | 12.2% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.6% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | · | -97.8% | -2.7% | 24.7% | 5.6% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | · | -70.3% | 8.6% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | · | -95.3% | -2.4% | 24.4% | 7.3% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | · | -61.6% | 9.2% | · | · | · | · | · | · | · | · | · |
Wycena (TTM) 14
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B | $2.92B | $2.62B | $2.27B | $1.86B | $1.68B | $1.36B | $1.30B | |
| Net Income TTM | $-144M | $22M | $475M | $486M | $391M | $364M | $252M | $226M | $123M | $155M | $149M | $127M | |
| Market Cap | $10.02B | $9.52B | $12.14B | $11.10B | $18.64B | $12.53B | $7.43B | $5.39B | $5.19B | $3.61B | $3.74B | $3.04B | |
| Enterprise Value | $9.81B | $9.33B | $11.86B | $10.87B | $18.40B | $12.34B | $7.23B | $6.84B | $6.12B | $4.70B | $4.46B | $3.64B | |
| P/E | -70.0 | 930.8 | 25.6 | 23.0 | 48.6 | 35.0 | 30.0 | 24.2 | 43.1 | 23.6 | 25.6 | 24.2 | |
| P/S | 2.5 | 2.4 | 2.9 | 2.8 | 5.3 | 4.3 | 2.8 | 2.4 | 2.8 | 2.1 | 2.7 | 2.3 | |
| P/B | 3.2 | 2.8 | 3.4 | 3.7 | 7.4 | 5.9 | 4.5 | 4.1 | 5.0 | 4.3 | 5.1 | 4.5 | |
| P / Tangible Book | 166.0 | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | 13.6 | 13.0 | 17.7 | 17.9 | 24.5 | 22.9 | 15.5 | 12.2 | 16.3 | 12.0 | 13.0 | 12.1 | |
| P / FCF | 19.3 | 19.0 | 33.2 | 37.6 | 35.0 | 33.0 | 21.8 | 17.9 | 22.0 | 14.7 | 16.6 | 15.6 | |
| EV / EBITDA | 22.9 | 15.8 | 12.7 | 11.4 | 21.5 | 18.5 | 13.2 | 13.9 | 14.6 | 12.9 | 14.8 | 13.3 | |
| EV / FCF | 18.9 | 18.6 | 32.5 | 36.9 | 34.6 | 32.5 | 21.2 | 22.7 | 26.0 | 19.2 | 19.8 | 18.6 | |
| EV / Revenue | 2.4 | 2.3 | 2.9 | 2.7 | 5.2 | 4.2 | 2.8 | 3.0 | 3.3 | 2.8 | 3.3 | 2.8 | |
| Earnings Yield | -1.4% | 0.11% | 3.9% | 4.3% | 2.1% | 2.9% | 3.3% | 4.1% | 2.3% | 4.2% | 3.9% | 4.1% |
Rachunek zysków i strat 14
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.00B | $996M | $994M | $1.00B | $1.03B | $984M | $1.00B | $1.01B | $1.03B | $1.01B | $1.01B | $1.03B | $1.03B | $1.10B | $989M | |
| Cost of Revenue | · | · | · | · | · | · | · | $661M | $672M | $667M | · | $665M | $652M | · | · | |
| SG&A Expense | $229M | $159M | $196M | $178M | $192M | $178M | $196M | $199M | $170M | $186M | $197M | $176M | $175M | $200M | $184M | |
| Operating Income | $120M | $120M | $-283M | $134M | $100M | $75M | $-168M | $117M | $152M | $126M | $133M | $152M | $168M | $164M | $151M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $35M | · | $34M | $34M | · | $11M | |
| Interest Income | $1M | $1M | $1M | $1M | $1M | $1M | $2M | $2M | $3M | $2M | $2M | $1M | $806.0K | $343.0K | $122.0K | |
| Other Non-op | $-37M | $-124M | $12M | $-23M | $154.0K | $-12M | $-23M | $3M | $-2M | $6M | $108M | $-6M | $-3M | $116M | $-17M | |
| Income Tax | $54M | $-15M | $-18M | $32M | $19M | $10M | $-3M | $21M | $25M | $25M | $20M | $25M | $27M | $56M | $25M | |
| Net Income | $-1M | $-15M | $-277M | $54M | $52M | $25M | $-214M | $70M | $94M | $73M | $187M | $87M | $103M | $187M | $96M | |
| EPS (Basic) | $-0.03 | $-0.30 | $-5.58 | $1.11 | $1.06 | $0.50 | $-4.20 | $1.34 | $1.75 | $1.31 | $3.65 | $1.70 | $2.02 | $3.68 | $1.90 | |
| EPS (Diluted) | $-0.03 | $-0.30 | $-5.57 | $1.10 | $1.06 | $0.50 | $-4.17 | $1.33 | $1.74 | $1.30 | $3.64 | $1.69 | $2.01 | $3.66 | $1.88 | |
| Shares (Basic) | 48,021,000 | 48,951,000 | -99,475,000 | 49,213,000 | 49,149,000 | 50,677,000 | -103,002,000 | 51,394,000 | 51,551,000 | 51,437,000 | 28,000 | 51,283,000 | 51,097,000 | -101,521,000 | 50,870,000 | |
| Shares (Diluted) | 48,021,000 | 48,951,000 | -100,031,000 | 49,426,000 | 49,316,000 | 50,853,000 | -103,643,000 | 51,583,000 | 51,846,000 | 51,842,000 | -42,000 | 51,607,000 | 51,428,000 | -102,590,000 | 51,283,000 | |
| EBITDA | $187M | $187M | · | $219M | $220M | $195M | · | $206M | $238M | $211M | · | $230M | $245M | · | $226M |
Bilans 28
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $192M | $192M | $214M | $207M | $183M | $229M | $195M | $210M | $179M | $327M | · | $157M | $202M | · | $194M | |
| Short-term Investments | · | · | · | · | · | · | · | · | · | · | · | · | · | · | $950.0K | |
| Receivables | $712M | $700M | $709M | $734M | $768M | $757M | $721M | $754M | $762M | $787M | · | $799M | $788M | · | $771M | |
| Inventory | $346M | $360M | $299M | $303M | $280M | $290M | $279M | $336M | $349M | $361M | · | $293M | $263M | · | $262M | |
| Prepaid Expense | $179M | $135M | $129M | $166M | $130M | $100M | $106M | $102M | $111M | $99M | · | $93M | $92M | · | $97M | |
| Current Assets | $1.53B | $1.49B | $1.45B | $1.53B | $1.47B | $1.51B | $1.40B | $1.49B | $1.50B | $1.67B | · | $1.44B | $1.45B | · | $1.42B | |
| PP&E (Net) | $1.49B | $1.51B | $1.66B | $1.59B | $1.61B | $1.59B | $1.60B | · | · | · | · | · | · | · | · | |
| PP&E (Gross) | $2.96B | $2.94B | $3.19B | $3.09B | $3.10B | $3.05B | $3.06B | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $1.46B | $1.43B | $1.54B | $1.50B | $1.50B | $1.46B | $1.45B | · | · | · | · | · | · | · | · | |
| Goodwill | $3.08B | $3.04B | $2.76B | $2.92B | $2.94B | $2.87B | $2.85B | $3.12B | $3.08B | $3.07B | · | $2.88B | $2.90B | · | $2.78B | |
| Intangibles | $253M | $249M | $340M | $571M | $602M | $656M | $723M | $778M | $800M | $828M | · | $886M | $958M | · | $968M | |
| Other Non-current Assets | $588M | $826M | $293M | $291M | $296M | $294M | $278M | $307M | $301M | $303M | · | $155M | $154M | · | $430M | |
| Total Assets | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Accounts Payable | $141M | $134M | $149M | $170M | $146M | $149M | $140M | $136M | $133M | $130M | · | $136M | $120M | · | $182M | |
| Accrued Liabilities | $380M | $372M | $270M | $229M | $232M | $242M | $232M | $208M | $192M | $191M | · | $198M | $221M | · | $197M | |
| Current Liabilities | $1.13B | $1.09B | $1.12B | $1.12B | $1.08B | $1.05B | $994M | $1.01B | $948M | $955M | · | $994M | $981M | · | $1.01B | |
| Capital Leases | $408M | $393M | $434M | $443M | $454M | $475M | $484M | $433M | $429M | $418M | · | $390M | $418M | · | $369M | |
| Deferred Tax | $79M | $81M | $95M | $123M | $109M | $107M | $107M | $168M | $165M | $180M | · | $185M | $212M | · | $196M | |
| Other Non-current Liabilities | $403M | $511M | $138M | $189M | $185M | $196M | $195M | $237M | $225M | $235M | · | $173M | $187M | · | $195M | |
| Total Liabilities | $4.64B | $4.74B | $3.92B | $4.06B | $4.16B | $4.34B | $4.02B | $4.18B | $4.18B | $4.45B | · | $4.26B | $4.54B | · | $4.71B | |
| Total Debt | $5M | $7M | · | $54.0K | $98.0K | $121.0K | · | $157.0K | $435.0K | $459.0K | · | $797.0K | · | · | $0 | |
| Common Stock | $496.0K | $493.0K | $492.0K | $514.0K | $513.0K | $512.0K | $511.0K | $517.0K | $517.0K | $515.0K | · | $514.0K | $512.0K | · | $510.0K | |
| Retained Earnings | $1.37B | $1.37B | $1.39B | $1.94B | $1.89B | $1.84B | $1.81B | $2.12B | $2.05B | $1.96B | · | $1.72B | $1.54B | · | $1.28B | |
| Treasury Stock | $323M | $210M | $0 | $363M | $363M | $357M | $0 | $120M | $18M | $9M | · | $24M | $19M | · | $38M | |
| AOCI | $-196M | $-191M | $-172M | $-192M | $-166M | $-265M | $-317M | $-193M | $-270M | $-250M | · | $-268M | $-239M | · | $-396M | |
| Stockholders' Equity | $2.84B | $2.94B | $3.16B | $3.41B | $3.35B | $3.19B | $3.46B | $3.78B | $3.72B | $3.64B | · | $3.31B | $3.11B | · | $2.63B | |
| Liabilities + Equity | $7.53B | $7.73B | $7.14B | $7.51B | $7.56B | $7.58B | $7.53B | $8.00B | $7.95B | $8.15B | · | $7.61B | $7.70B | · | $7.38B | |
| Shares Outstanding | 47,728,000 | 48,167,000 | 49,217,000 | 49,215,000 | 49,209,000 | 49,115,000 | 51,141,000 | 51,134,000 | 51,613,000 | 51,510,000 | · | 51,296,000 | 51,182,000 | 50,944,000 | 50,877,000 |
Przepływy pieniężne 16
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $67M | $67M | $78M | $85M | $120M | $120M | $102M | $88M | $86M | $85M | $81M | $79M | $77M | $78M | $75M | |
| Stock-based Comp | $20M | $22M | $18M | $23M | $17M | $13M | $17M | $19M | $17M | $17M | $20M | $23M | $13M | $22M | $22M | |
| Amort. of Intangibles | $15M | $15M | $21M | $27M | $65M | $65M | $41M | $32M | $32M | $33M | $34M | $34M | $35M | $35M | $36M | |
| Restructuring | $23M | $32M | $26M | $17M | $32M | $24M | $41M | $31M | $18M | $17M | $8M | $15M | $3M | $4M | $1M | |
| Other Non-cash | · | $-34M | · | · | · | $13M | · | · | · | $-45M | · | · | $-84M | · | · | |
| Operating Cash Flow | $180M | $41M | $148M | $214M | $205M | $172M | $159M | $252M | $194M | $130M | $221M | $205M | $109M | $235M | $133M | |
| CapEx | $31M | $56M | $89M | $36M | $35M | $59M | $76M | $39M | $39M | $79M | $78M | $66M | $107M | $89M | $72M | |
| Investing Cash Flow | $28M | $-408M | $-93M | $-34M | $-37M | $-45M | $-76M | $-21M | $-62M | $-86M | $-238M | $-80M | $-169M | $44M | $-92M | |
| Debt Issued | $353M | $912M | $157M | $107M | $547M | $416M | $105M | $236M | $440M | $301M | $443M | $51M | $192M | $154M | $618M | |
| Net Debt Issued | · | $912M | · | · | · | $416M | · | · | · | $301M | · | · | $192M | · | · | |
| Stock Repurchased | $116M | $208M | $96.0K | $93.0K | $7M | $353M | $124.0K | $101M | $9M | $9M | $139.0K | $38.0K | $19M | $159.0K | $24.0K | |
| Net Stock Activity | · | $-208M | · | · | · | $-353M | · | · | · | $-9M | · | · | $-19M | · | · | |
| Financing Cash Flow | $-165M | $348M | $-52M | $-153M | $-227M | $-105M | $-76M | $-208M | $-286M | $18M | $124M | $-163M | $25M | $-249M | $-52M | |
| Net Change in Cash | $42M | $-18M | $7M | $24M | $-47M | $26M | $-6M | $31M | $-158M | $54M | $119M | $-43M | $-32M | $45M | $-11M | |
| Taxes Paid | $16M | $2M | $27M | $19M | $57M | $17M | $31M | $23M | $53M | $19M | $15M | $14M | $14M | · | · | |
| Free Cash Flow | · | $-15M | · | · | · | $112M | · | · | · | $51M | · | · | $3M | · | · |
Rentowność 5
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 11.9% | 12.0% | · | 13.3% | 9.7% | 7.6% | · | 11.6% | 14.8% | 12.4% | · | 14.8% | 16.3% | · | 15.3% | |
| Net Margin | -0.15% | -1.5% | · | 5.4% | 5.1% | 2.6% | · | 6.9% | 9.2% | 7.2% | · | 8.5% | 10.0% | · | 9.8% | |
| EBITDA Margin | 18.6% | 18.8% | · | 21.8% | 21.3% | 19.8% | · | 20.4% | 23.2% | 20.9% | · | 22.4% | 23.8% | · | 22.8% | |
| ROA | -0.02% | -0.19% | · | 0.70% | 0.67% | 0.32% | · | 0.89% | 1.2% | 0.92% | · | 1.2% | · | · | 1.3% | |
| ROE | -0.05% | -0.48% | · | 1.5% | 1.5% | 0.75% | · | 2.0% | 2.7% | 2.2% | · | 2.9% | · | · | 3.8% |
Płynność i wypłacalność 4
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.3 | 1.4 | · | 1.4 | 1.4 | 1.4 | · | 1.5 | 1.6 | 1.7 | · | 1.5 | · | · | 1.4 | |
| Quick Ratio | 0.8 | 0.8 | · | 0.8 | 0.9 | 0.9 | · | 1.0 | 1.0 | 1.2 | · | 1.0 | · | · | 1.0 | |
| Debt / Equity | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | · | · | 0.0 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 3.6 | · | 4.5 | 4.9 | · | 13.3 |
Efektywność 3
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | · | · | 0.1 | |
| Inventory Turnover | · | · | · | · | · | · | · | 2.1 | 2.1 | 2.1 | · | · | · | · | · | |
| Receivables Turnover | 1.4 | 1.4 | · | 1.4 | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.3 | · | 1.3 | · | · | 1.4 |
Wycena (TTM) 13
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $4.04B | $4.02B | · | $4.03B | $4.05B | $4.03B | · | $4.07B | $4.12B | $4.13B | · | $4.11B | $3.91B | · | $3.77B | |
| Net Income TTM | $90M | $117M | · | $202M | $242M | $262M | · | $324M | $351M | $360M | · | $384M | $402M | · | $402M | |
| Market Cap | $10.30B | $7.67B | · | $7.31B | $7.38B | $7.64B | · | $10.14B | $10.66B | $13.96B | · | $10.05B | · | · | $9.54B | |
| Enterprise Value | $10.11B | $7.48B | · | $7.10B | $7.20B | $7.41B | · | $9.93B | $10.48B | $13.63B | · | $9.90B | · | · | $9.35B | |
| P/E | 117.9 | 67.4 | · | 37.2 | 32.4 | 31.9 | · | 32.7 | 31.2 | 39.3 | · | 26.2 | 25.8 | · | 23.9 | |
| P/S | 2.6 | 1.9 | · | 1.8 | 1.8 | 1.9 | · | 2.5 | 2.6 | 3.4 | · | 2.4 | · | · | 2.5 | |
| P/B | 3.6 | 2.6 | · | 2.1 | 2.2 | 2.4 | · | 2.7 | 2.9 | 3.8 | · | 3.0 | · | · | 3.6 | |
| P / Cash Flow | · | 186.6 | · | · | · | 44.5 | · | · | · | 107.5 | · | · | · | · | · | |
| P / FCF | · | -516.9 | · | · | · | 68.0 | · | · | · | 275.0 | · | · | · | · | · | |
| EV / EBITDA | 54.0 | 40.0 | · | 32.4 | 32.8 | 38.0 | · | 48.3 | 44.1 | 64.5 | · | 43.0 | · | · | 41.4 | |
| EV / FCF | · | -504.4 | · | · | · | 65.9 | · | · | · | 268.6 | · | · | · | · | · | |
| EV / Revenue | 2.5 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.4 | 2.5 | 3.3 | · | 2.4 | · | · | 2.5 | |
| Earnings Yield | 0.85% | 1.5% | · | 2.7% | 3.1% | 3.1% | · | 3.1% | 3.2% | 2.5% | · | 3.8% | 3.9% | · | 4.2% |
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
Rachunek zysków i strat
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Przychody | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Marża Operacyjna % | 0.63% | 5.6% | 14.9% | 16.4% | 16.7% |
| Zysk netto | $-144M | $22M | $475M | $486M | $391M |
| Rozwodniony EPS | $-2.91 | $0.20 | $9.22 | $9.48 | $7.60 |
Bilans
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Wskaźnik bieżący | 1.3 | 1.4 | 1.5 | 1.3 | 1.2 |
| Wskaźnik Szybkości | 0.8 | 0.9 | 1.0 | 0.9 | 0.9 |
Przepływy pieniężne
| 2025-12-27 | 2024-12-28 | 2023-12-30 | 2022-12-31 | 2021-12-25 | |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $518M | $502M | $365M | $295M | $532M |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
📊
Wybierz metryki, które są dla Ciebie ważne — kliknij ➕ obok dowolnego wiersza w Pełnych Fundamentach powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.
Właściciele instytucjonalni (13F) 616 emitentów · $7.8B łącznie · Na dzień 30 czerwca 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
Aktywność instytucjonalna — Q2 2026 vs poprzedni kwartał
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 82 (-1 vs poprzedni kw.) | 59 (-23 vs poprzedni kw.) | 180 (-11 vs poprzedni kw.) | 201 (+15 vs poprzedni kw.) | +5.0M |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| FMR LLC | $737 350 307 | 3 251 247 | 9,42% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $714 227 026 | 3 149 288 | 9,12% | Akcje |
| HARRIS ASSOCIATES L P | $508 269 048 | 2 241 144 | 6,49% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $501 427 927 | 2 210 979 | 6,40% | Akcje |
| STATE STREET CORP | $422 800 968 | 1 864 284 | 5,40% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $348 883 077 | 1 538 354 | 4,46% | Akcje |
| CITADEL ADVISORS LLC | $270 696 771 | 1 193 601 | 3,46% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $259 130 041 | 1 144 937 | 3,31% | Akcje |
| EARNEST PARTNERS LLC | $254 007 295 | 1 120 011 | 3,24% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $223 361 616 | 984 883 | 2,85% | Akcje |
| AMERIPRISE FINANCIAL INC | $192 886 814 | 850 503 | 2,46% | Akcje |
| NEUBERGER BERMAN GROUP LLC | $192 182 793 | 847 488 | 2,45% | Akcje |
| Clearbridge Investments, LLC | $177 185 527 | 781 276 | 2,26% | Akcje |
| COOKE & BIELER LP | $171 369 328 | 755 630 | 2,19% | Akcje |
| VICTORY CAPITAL MANAGEMENT INC | $150 762 735 | 664 768 | 1,93% | Akcje |
| MILLENNIUM MANAGEMENT LLC | $110 324 717 | 486 462 | 1,41% | Akcje |
| BANK OF AMERICA CORP /DE/ | $104 921 899 | 462 639 | 1,34% | Akcje |
| Gotham Asset Management, LLC | $98 233 181 | 433 146 | 1,25% | Akcje |
| Amundi | $93 528 650 | 412 402 | 1,19% | Akcje |
| NORGES BANK | $83 921 372 | 370 040 | 1,07% | Akcje |
| MARSHALL WACE, LLP | $76 947 125 | 339 288 | 0,98% | Akcje |
| Iron Triangle Partners LP | $75 748 141 | 379 728 | 0,97% | Akcje |
| ALLIANCEBERNSTEIN L.P. | $64 615 913 | 374 585 | 0,83% | Akcje |
| SNYDER CAPITAL MANAGEMENT L P | $63 899 443 | 281 756 | 0,82% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $63 174 169 | 278 558 | 0,81% | Akcje |
| BNP PARIBAS FINANCIAL MARKETS | $63 095 473 | 278 211 | 0,81% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $61 384 115 | 270 665 | 0,78% | Akcje |
| PRIMECAP MANAGEMENT CO/CA/ | $60 523 448 | 266 870 | 0,77% | Akcje |
| GOLDMAN SACHS GROUP INC | $57 319 812 | 252 744 | 0,73% | Akcje |
| Meridiem Capital Partners LP | $56 012 367 | 246 979 | 0,72% | Akcje |
| Alyeska Investment Group, L.P. | $53 295 650 | 235 000 | 0,68% | Akcje |
| Quantinno Capital Management LP | $49 020 824 | 216 150 | 0,63% | Akcje |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $48 415 129 | 213 480 | 0,62% | Akcje |
| Boston Trust Walden Corp | $46 506 918 | 205 066 | 0,59% | Akcje |
| Burgundy Asset Management Ltd. | $45 453 909 | 278 329 | 0,58% | Akcje |
| SRS Investment Management, LLC | $42 496 817 | 187 384 | 0,54% | Akcje |
| LOOMIS SAYLES & CO L P | $38 517 487 | 169 838 | 0,49% | Akcje |
| JONES FINANCIAL COMPANIES LLLP | $37 184 513 | 172 350 | 0,47% | Akcje |
| PERCEPTIVE ADVISORS LLC | $31 750 600 | 140 000 | 0,41% | Akcje |
| LAKEWOOD CAPITAL MANAGEMENT, LP | $30 389 860 | 134 000 | 0,39% | Akcje |
| NEW YORK STATE COMMON RETIREMENT FUND | $29 879 583 | 131 750 | 0,38% | Akcje |
| BlackRock, Inc. | $29 025 945 | 127 986 | 0,37% | Akcje |
| PICTON MAHONEY ASSET MANAGEMENT | $26 340 305 | 116 144 | 0,34% | Akcje |
| FIL Ltd | $25 184 576 | 111 048 | 0,32% | Akcje |
| Candriam S.C.A. | $23 824 478 | 105 152 | 0,30% | Akcje |
| Clark Capital Management Group, Inc. | $23 010 567 | 101 462 | 0,29% | Akcje |
| Vanguard Global Advisers, LLC | $22 453 344 | 99 005 | 0,29% | Akcje |
| Swiss National Bank | $22 452 210 | 99 000 | 0,29% | Akcje |
| CONFLUENCE INVESTMENT MANAGEMENT LLC | $20 491 384 | 90 354 | 0,26% | Akcje |
| ENVESTNET ASSET MANAGEMENT INC | $20 280 546 | 89 424 | 0,26% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $19 730 730 | 87 000 | 0,25% | Opcja kupna |
| NOMURA HOLDINGS INC | $19 672 672 | 86 744 | 0,25% | Akcje |
| RHUMBLINE ADVISERS | $19 484 825 | 85 916 | 0,25% | Akcje |
| Ilex Capital Partners (UK) LLP | $18 413 760 | 81 193 | 0,24% | Akcje |
| Aristotle Capital Boston, LLC | $18 273 438 | 80 574 | 0,23% | Akcje |
| CITADEL ADVISORS LLC | $17 485 509 | 77 100 | 0,22% | Opcja kupna |
| NICHOLAS COMPANY, INC. | $16 305 067 | 71 895 | 0,21% | Akcje |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $15 172 024 | 66 899 | 0,19% | Akcje |
| Mitsubishi UFJ Asset Management Co., Ltd. | $15 164 087 | 66 864 | 0,19% | Akcje |
| Ranger Investment Management, L.P. | $15 009 416 | 66 182 | 0,19% | Akcje |
| California Public Employees Retirement System | $14 670 818 | 64 689 | 0,19% | Akcje |
| Assenagon Asset Management S.A. | $14 020 385 | 61 821 | 0,18% | Akcje |
| ASSETMARK, INC | $13 939 194 | 61 463 | 0,18% | Akcje |
| Rhenman & Partners Asset Management AB | $12 972 388 | 57 200 | 0,17% | Akcje |
| RIVERBRIDGE PARTNERS LLC | $12 859 587 | 56 703 | 0,16% | Akcje |
| TD Asset Management Inc | $12 854 230 | 56 679 | 0,16% | Akcje |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $12 836 314 | 56 600 | 0,16% | Opcja sprzedaży |
| Laurus Investment Counsel Inc. | $12 365 663 | 71 685 | 0,16% | Akcje |
| KING LUTHER CAPITAL MANAGEMENT CORP | $12 204 023 | 53 812 | 0,16% | Akcje |
| FRONTIER CAPITAL MANAGEMENT CO LLC | $11 552 133 | 50 938 | 0,15% | Akcje |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $10 732 081 | 47 278 | 0,14% | Akcje |
| RAYMOND JAMES FINANCIAL INC | $10 506 727 | 46 328 | 0,13% | Akcje |
| VANGUARD ASSET MANAGEMENT, Ltd | $10 472 482 | 46 177 | 0,13% | Akcje |
| KENNEDY CAPITAL MANAGEMENT LLC | $9 914 950 | 43 719 | 0,13% | Akcje |
| BARCLAYS PLC | $9 909 816 | 43 696 | 0,13% | Akcje |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $9 827 670 | 56 972 | 0,13% | Akcje |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $9 382 529 | 41 371 | 0,12% | Akcje |
| Park West Asset Management LLC | $9 343 748 | 41 200 | 0,12% | Akcje |
| State of Tennessee, Department of Treasury | $8 457 000 | 37 290 | 0,11% | Akcje |
| J.P. Marvel Investment Advisors, LLC | $8 456 092 | 37 286 | 0,11% | Akcje |
| CASTLEARK MANAGEMENT LLC | $8 174 646 | 36 045 | 0,10% | Akcje |
| JANE STREET GROUP, LLC | $7 869 613 | 34 700 | 0,10% | Opcja kupna |
| Pine Ridge Advisers LLC | $7 710 860 | 34 000 | 0,10% | Akcje |
| PRUDENTIAL FINANCIAL INC | $7 346 635 | 32 394 | 0,09% | Akcje |
| Capricorn Fund Managers Ltd | $7 092 630 | 31 274 | 0,09% | Akcje |
| STATE OF WISCONSIN INVESTMENT BOARD | $7 000 554 | 30 868 | 0,09% | Akcje |
| FIRST TRUST ADVISORS LP | $6 951 290 | 30 651 | 0,09% | Akcje |
| Caption Management, LLC | $6 803 700 | 30 000 | 0,09% | Opcja sprzedaży |
| Engineers Gate Manager LP | $6 637 463 | 29 267 | 0,08% | Akcje |
| LAWSON KROEKER INVESTMENT MANAGEMENT INC/NE | $6 351 027 | 28 004 | 0,08% | Akcje |
| Midwest Trust Co | $6 091 126 | 26 858 | 0,08% | Akcje |
| VAN ECK ASSOCIATES CORP | $5 942 578 | 26 203 | 0,08% | Akcje |
| SEI INVESTMENTS CO | $5 929 630 | 26 150 | 0,08% | Akcje |
| Sendero Wealth Management, LLC | $5 909 468 | 26 057 | 0,08% | Akcje |
| 13D Management LLC | $5 851 182 | 25 800 | 0,07% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $5 500 853 | 31 889 | 0,07% | Akcje |
| D. E. Shaw & Co., Inc. | $5 462 691 | 24 087 | 0,07% | Akcje |
| INVESTMENT HOUSE LLC | $5 447 042 | 24 018 | 0,07% | Akcje |
| LPL Financial LLC | $5 409 169 | 23 851 | 0,07% | Akcje |
| LRT Capital Management, LLC | $5 348 842 | 23 585 | 0,07% | Akcje |
Insiderzy spółki 57 insiderów · 21 dyrektorzy generalni · 27 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Glenn Coleman | EVP & Chief Financial Officer | 29 maja 2026 A | 27 752 | 0 | 0 | $0 |
| Flavia Pease | Corporate Executive VP & CFO | 31 maja 2025 F | 17 297 | 0 | 0 | $0 |
| David Ross Smith | Corporate Executive VP & CFO | 3 marca 2022 M | 25 819 | 0 | 0 | $0 |
| Davide Molho | President & COO | 24 lipca 2018 M | 17 155 | 0 | 0 | $0 |
| Mark Mintz | EVP, Chief Information Officer | 31 maja 2026 F | 9 546 | 0 | 0 | $0 |
| William D Barbo | Corporate Executive VP & CCO | 7 listopada 2024 G | 23 337 | 0 | 0 | $0 |
| John W Kuo | CEVP General Counsel & CCO | 1 czerwca 2020 A | 3 171 | 0 | 0 | $0 |
| David P Johst | Corporate Executive VP | 29 maja 2020 A | 224 478 | 0 | 0 | $0 |
| John J Crowley | SVP, Chief Accounting Officer | 1 października 2016 F | 5 599 | 0 | 0 | $0 |
| Nancy Gillett | Corporate Executive VP | 2 marca 2016 S | 11 034 | 0 | 0 | $0 |
| Jorg Geller | Corporate Executive VP | 25 lutego 2015 M | 14 094 | 0 | 0 | $0 |
| RENAUD REAL H | Corp. Executive VP | 11 sierpnia 2010 F | 74 390 | 0 | 0 | $0 |
| Christopher Berthoux | Executive Vice President | 26 lutego 2010 A | 31 897 | 0 | 0 | $0 |
| Joanne P Acford | Corp. Sr VP, GC and Corp. Sec | 11 sierpnia 2007 F | 37 109 | 0 | 0 | $0 |
| David J Elliott | Officer | 29 czerwca 2007 M | 11 750 | 0 | 0 | $0 |
| Cheri L Walker | Corporate Senior VP | 1 maja 2007 A | 6 262 | 0 | 0 | $0 |
| Stephanie B Wells | Senior Vice President | 2 kwietnia 2007 A | 11 500 | 0 | 0 | $0 |
| Nicholas Ventresca | Senior Vice President | 2 kwietnia 2007 F | 12 713 | 0 | 0 | $0 |
| John C Ho | Senior Vice President | 23 lutego 2007 A | 12 710 | 0 | 0 | $0 |
| Brian Bathgate | Corporate Vice President | 27 lutego 2006 S | 16 134 | 0 | 0 | $0 |
| Alastair Stuart Mcewan | Corporate VP | 23 grudnia 2004 M | 8 000 | 0 | 0 | $0 |
| Steven Barg | Dyrektor | 2 czerwca 2026 A | 3 287 | 0 | 0 | $0 |
| Nancy C Andrews | Dyrektor | 12 maja 2026 G | 3 964 | 0 | 0 | $0 |
| Reshema Kemps-Polanco | Dyrektor | 8 maja 2026 A | 4 563 | 0 | 0 | $0 |
| George Llado | Dyrektor | 8 maja 2026 A | 6 702 | 0 | 0 | $0 |
| Abraham Ceesay | Dyrektor | 8 maja 2026 A | 2 384 | 0 | 0 | $0 |
| Mark J Enyedy | Dyrektor | 8 maja 2026 A | 2 384 | 0 | 0 | $0 |
| Paul W Graves | Dyrektor | 8 maja 2026 A | 2 384 | 0 | 0 | $0 |
| Craig B. Thompson | Dyrektor | 8 maja 2026 A | 3 851 | 0 | 0 | $0 |
| Martin Mackay | Dyrektor | 8 maja 2026 A | 17 137 | 0 | 0 | $0 |
| Virginia M Wilson | Dyrektor | 8 maja 2026 A | 6 349 | 0 | 0 | $0 |
| George Massaro | Dyrektor | 15 maja 2025 S | 5 575 | 0 | 0 | $0 |
| Richard F Wallman | Dyrektor | 7 listopada 2024 S | 0 | 0 | 0 | $0 |
| Deborah Turner Kochevar | Dyrektor | 13 maja 2024 A | 7 894 | 0 | 0 | $0 |
| Robert J Bertolini | Dyrektor | 13 maja 2024 A | 32 802 | 0 | 0 | $0 |
| Richard C Reese | Dyrektor | 15 maja 2023 A | 65 541 | 0 | 0 | $0 |
| George M Milne JR | Dyrektor | 7 maja 2021 A | 29 079 | 0 | 0 | $0 |
| Stephen D Chubb | Dyrektor | 23 lutego 2021 M | 40 529 | 0 | 0 | $0 |
| Jean-Paul Mangeolle | Dyrektor | 22 maja 2019 A | 3 886 | 0 | 0 | $0 |
| William Waltrip | Dyrektor | 5 grudnia 2012 S | 21 830 | 0 | 0 | $0 |
| Samuel O Thier MD | Dyrektor | 9 maja 2012 A | 18 230 | 0 | 0 | $0 |
| Douglas E Rogers | Dyrektor | 7 maja 2010 A | 12 859 | 0 | 0 | $0 |
| Nancy T Chang | Dyrektor | 7 maja 2010 A | 31 010 | 0 | 0 | $0 |
| Linda Mcgoldrick | Dyrektor | 13 lutego 2006 A | — | 0 | 0 | $0 |
| Walter S Nimmo | Dyrektor | 25 lutego 2005 S | 149 447 | 0 | 0 | $0 |
| John Urquhart | Dyrektor | 17 lutego 2005 A | 11 738 | 0 | 0 | $0 |
| Louise S Mccrary | Dyrektor | 17 lutego 2005 A | — | 0 | 0 | $0 |
| Robert Cawthorn | Dyrektor | 2 czerwca 2004 G | 278 600 | 0 | 0 | $0 |
| Shannon M Parisotto | — | 11 sierpnia 2026 M | 4 807 | 0 | 2 | $-2 365 755 |
| Birgit Girshick | — | 11 sierpnia 2026 M | 36 013 | 0 | 1 | $-1 819 350 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Aktywiści i właściciele 5%+ 6 akcji
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| JANA PARTNERS LLC ×4 zgłoszenia | 4 sierpnia 2011 | — | Pierwotne zgłoszenie | — | SEC |
| Relational Investors, LLC, Relational Investors Mid-Cap Fund I, L.P., Relational Investors Mid-Cap Fund II, L.P., Ralph V. Whitworth, David H. Batchelder, California State Teachers’ Retirement System ×3 zgłoszenia | 9 lutego 2011 | — | Pierwotne zgłoszenie | — | SEC |
| Neuberger Berman Group LLC, Neuberger Berman LLC, Neuberger Berman Management ×3 zgłoszenia | 7 grudnia 2010 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 16 czerwca 2010 | — | Pierwotne zgłoszenie | — | SEC |
| Niezgłoszona osoba raportująca | 7 czerwca 2010 | — | Pierwotne zgłoszenie | Inwestycja pasywna | SEC |
| Charles River Laboratories International, Inc. IRS No. 061397316 | 5 maja 2010 | — | Pierwotne zgłoszenie | Kampania zarządu | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Posiadanie ETF-ów Posiadane przez 135 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| RSPH · Invesco Exchange-Traded Fund Trust | 2,18% | 63 652 SH | 8 sierpnia 2026 | Dziennie |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1,49% | 4 749 NS | 30 kwietnia 2026 | N-PORT |
| EPSB · Harbor ETF Trust | 1,33% | 370 NS | 30 kwietnia 2026 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 1,18% | 41 597 SH | 8 sierpnia 2026 | Dziennie |
| EPMV · Harbor ETF Trust | 1,09% | 291 NS | 30 kwietnia 2026 | N-PORT |
| IBB · iShares Trust | 0,97% | 349 491 SH | 8 sierpnia 2026 | Dziennie |
| EPSV · Harbor ETF Trust | 0,90% | 270 NS | 30 kwietnia 2026 | N-PORT |
| TAX · EA Series Trust | 0,80% | 1 131 NS | 29 maja 2026 | N-PORT |
| LSEQ · Harbor ETF Trust | 0,66% | 612 NS | 30 kwietnia 2026 | N-PORT |
| HIBL · Direxion Shares ETF Trust | 0,50% | 2 356 NS | 30 kwietnia 2026 | N-PORT |
| ISCV · iShares Trust | 0,40% | 10 497 SH | 8 sierpnia 2026 | Dziennie |
| FNY · First Trust Exchange-Traded AlphaDE… | 0,38% | 11 925 NS | 30 kwietnia 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0,38% | 25 401 SH | 8 sierpnia 2026 | Dziennie |
| VGHY · VANGUARD FIXED INCOME SECURITIES FU… | 0,36% | 1 145 000 PA | 8 sierpnia 2026 | Dziennie |
| IQSM · New York Life Investments ETF Trust | 0,33% | 6 161 NS | 30 kwietnia 2026 | N-PORT |
| FFSM · FIDELITY COVINGTON TRUST | 0,29% | 22 440 NS | 30 kwietnia 2026 | N-PORT |
| RSP · Invesco Exchange-Traded Fund Trust | 0,27% | 996 151 SH | 8 sierpnia 2026 | Dziennie |
| DFAT · Dimensional ETF Trust | 0,26% | 212 321 NS | 30 kwietnia 2026 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0,23% | 701 498 SH | 8 sierpnia 2026 | Dziennie |
| ESML · iShares Trust | 0,23% | 24 979 SH | 8 sierpnia 2026 | Dziennie |
| BKMC · BNY Mellon ETF Trust | 0,22% | 8 115 NS | 30 kwietnia 2026 | N-PORT |
| IYH · iShares Trust | 0,21% | 29 370 SH | 8 sierpnia 2026 | Dziennie |
| ISCB · iShares Trust | 0,20% | 2 125 SH | 8 sierpnia 2026 | Dziennie |
| SMMD · iShares Trust | 0,17% | 24 455 SH | 8 sierpnia 2026 | Dziennie |
| FSMD · FIDELITY COVINGTON TRUST | 0,17% | 24 528 NS | 30 kwietnia 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0,17% | 133 341 NS | 31 maja 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,16% | 138 243 NS | 30 kwietnia 2026 | N-PORT |
| IXJ · iShares Trust | 0,16% | 25 598 SH | 8 sierpnia 2026 | Dziennie |
| VHT · VANGUARD WORLD FUND | 0,16% | 148 331 SH | 8 sierpnia 2026 | Dziennie |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0,15% | 18 369 NS | 30 kwietnia 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,15% | 6 079 NS | 31 maja 2026 | N-PORT |
| WSML · iShares Trust | 0,13% | 6 018 SH | 8 sierpnia 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,13% | 22 674 NS | 30 kwietnia 2026 | N-PORT |
| DFSV · Dimensional ETF Trust | 0,13% | 59 338 NS | 30 kwietnia 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0,13% | 1 102 914 SH | 8 sierpnia 2026 | Dziennie |
| VGMS · VANGUARD MALVERN FUNDS | 0,13% | 315 000 PA | 8 sierpnia 2026 | Dziennie |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,13% | 4 072 SH | 8 sierpnia 2026 | Dziennie |
| RXL · ProShares Trust | 0,13% | 513 NS | 31 maja 2026 | N-PORT |
| IWS · iShares Trust | 0,13% | 74 284 SH | 8 sierpnia 2026 | Dziennie |
| REVS · Columbia ETF Trust I | 0,12% | 2 082 NS | 30 kwietnia 2026 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0,12% | 982 NS | 30 kwietnia 2026 | N-PORT |
| SMLF · iShares Trust | 0,12% | 18 532 SH | 8 sierpnia 2026 | Dziennie |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,11% | 3 280 NS | 30 kwietnia 2026 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0,11% | 1 032 NS | 30 kwietnia 2026 | N-PORT |
| IWR · iShares Trust | 0,09% | 199 595 SH | 8 sierpnia 2026 | Dziennie |
| AVMC · AMERICAN CENTURY ETF TRUST | 0,09% | 1 986 NS | 31 maja 2026 | N-PORT |
| IEUS · iShares Trust | 0,09% | 4 951 SH | 8 sierpnia 2026 | Dziennie |
| XOEF · iShares Trust | 0,07% | 61 SH | 8 sierpnia 2026 | Dziennie |
| VSDB · VANGUARD MALVERN FUNDS | 0,07% | 635 000 PA | 8 sierpnia 2026 | Dziennie |
| FNX · First Trust Exchange-Traded AlphaDE… | 0,07% | 5 261 NS | 30 kwietnia 2026 | N-PORT |